| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease (NCT07717411) | Hoffmann-La Roche | 2026-11-30 |
| A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis (NCT07749157) | Hoffmann-La Roche | 2026-11-23 |
| A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight (NCT07589686) | Hoffmann-La Roche | 2026-09-30 |
| A COPD Data Registry for Participants With Frequent Exacerbations (NCT07059273) | Hoffmann-La Roche | 2026-09-14 |
| A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) (NCT07416552) | Hoffmann-La Roche | 2026-09-08 |
| A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes (NCT07748208) | Hoffmann-La Roche | 2026-09-01 |
| A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (NCT07541170) | Hoffmann-La Roche | 2026-09-01 |
| A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A (NCT07226206) | Hoffmann-La Roche | 2026-09-01 |
| A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease (NCT07298421) | Hoffmann-La Roche | 2026-08-31 |
| A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions (NCT07741604) | Hoffmann-La Roche | 2026-08-03 |
| A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (NCT07503340) | Hoffmann-La Roche | 2026-08-01 |
| A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA) (NCT07531719) | Hoffmann-La Roche | 2026-07-22 |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes (NCT07670416) | Hoffmann-La Roche | 2026-07-03 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants (NCT07626515) | Hoffmann-La Roche | 2026-07-02 |
| An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis (NCT07665723) | Hoffmann-La Roche | 2026-06-29 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (NCT07555938) | Hoffmann-La Roche | 2026-06-23 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy (NCT07588100) | Hoffmann-La Roche | 2026-06-18 |
| An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis (NCT07620392) | Hoffmann-La Roche | 2026-06-03 |
| A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis (NCT07598396) | Hoffmann-La Roche | 2026-05-25 |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A (NCT07416526) | Hoffmann-La Roche | 2026-05-15 |
| A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT05199688) | Hoffmann-La Roche | 2026-05-06 |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A (NCT07416604) | Hoffmann-La Roche | 2026-04-27 |
| A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis (NCT07158242) | Hoffmann-La Roche | 2026-04-15 |
| A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer (NCT07405801) | Hoffmann-La Roche | 2026-04-07 |
| A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease (NCT07495813) | Hoffmann-La Roche | 2026-03-31 |
| A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight (NCT07499050) | Hoffmann-La Roche | 2026-03-30 |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes (NCT07351058) | Hoffmann-La Roche | 2026-03-23 |
| A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) (NCT07172022) | Hoffmann-La Roche | 2026-03-16 |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes (NCT07351045) | Hoffmann-La Roche | 2026-03-16 |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT07287150) | Hoffmann-La Roche | 2026-03-11 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (NCT07282574) | Hoffmann-La Roche | 2026-03-10 |
| A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization (NCT07527741) | Hoffmann-La Roche | 2026-02-23 |
| A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury (NCT07455136) | Hoffmann-La Roche | 2026-02-09 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer (NCT07323576) | Hoffmann-La Roche | 2026-02-01 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) (NCT07234942) | Hoffmann-La Roche | 2026-01-27 |
| A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (NCT07347600) | Hoffmann-La Roche | 2026-01-21 |
| A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis (NCT07223697) | Hoffmann-La Roche | 2026-01-08 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants (NCT07271693) | Hoffmann-La Roche | 2025-12-22 |
| A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) (NCT07137598) | Hoffmann-La Roche | 2025-12-05 |
| A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (NCT06847542) | Hoffmann-La Roche | 2025-11-27 |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease (NCT07174310) | Hoffmann-La Roche | 2025-11-24 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease (NCT07246941) | Hoffmann-La Roche | 2025-11-19 |
| A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (NCT07074886) | Hoffmann-La Roche | 2025-11-13 |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (NCT07170150) | Hoffmann-La Roche | 2025-11-12 |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT06793215) | Hoffmann-La Roche | 2025-10-24 |
| A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) (NCT07161258) | Hoffmann-La Roche | 2025-10-06 |
| A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity (NCT07137585) | Hoffmann-La Roche | 2025-09-30 |
| An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma (NCT07200375) | Hoffmann-La Roche | 2025-09-29 |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (NCT07169578) | Hoffmann-La Roche | 2025-09-17 |
| A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer (NCT07054190) | Hoffmann-La Roche | 2025-09-09 |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes (NCT07112872) | Hoffmann-La Roche | 2025-08-19 |
| A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity (NCT07081958) | Hoffmann-La Roche | 2025-07-29 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (NCT06961370) | Hoffmann-La Roche | 2025-07-16 |
| A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice (NCT07284121) | Hoffmann-La Roche | 2025-07-15 |
| A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (NCT07025811) | Hoffmann-La Roche | 2025-07-09 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis (NCT07483450) | Hoffmann-La Roche | 2025-07-04 |
| A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease (NCT06998524) | Hoffmann-La Roche | 2025-06-27 |
| A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC) (NCT06816017) | Hoffmann-La Roche | 2025-06-15 |
| A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma (NCT06934044) | Hoffmann-La Roche | 2025-05-13 |
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (NCT06819891) | Hoffmann-La Roche | 2025-05-12 |
| A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity (NCT06965413) | Hoffmann-La Roche | 2025-05-05 |
| Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy (NCT06862869) | Hoffmann-La Roche | 2025-04-30 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) (NCT06884618) | Hoffmann-La Roche | 2025-04-30 |
| An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment (NCT06883240) | Hoffmann-La Roche | 2025-04-29 |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT06624085) | Hoffmann-La Roche | 2025-04-28 |
| Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus (NCT06704672) | Hoffmann-La Roche | 2025-04-14 |
| A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis (NCT06903065) | Hoffmann-La Roche | 2025-04-14 |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (NCT06790693) | Hoffmann-La Roche | 2025-04-09 |
| A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) (NCT06450639) | Hoffmann-La Roche | 2025-04-04 |
| A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis (NCT06863961) | Hoffmann-La Roche | 2025-04-01 |
| A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (NCT06819878) | Hoffmann-La Roche | 2025-03-17 |
| A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (NCT06795048) | Hoffmann-La Roche | 2025-03-14 |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT06806033) | Hoffmann-La Roche | 2025-03-05 |
| A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease (NCT06826612) | Hoffmann-La Roche | 2025-02-21 |
| A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081 (NCT06809608) | Hoffmann-La Roche | 2025-02-13 |
| A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) (NCT06680817) | Hoffmann-La Roche | 2025-02-05 |
| A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants (NCT06733298) | Hoffmann-La Roche | 2025-01-08 |
| A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME) (NCT06723288) | Hoffmann-La Roche | 2024-12-31 |
| Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis (NCT06975436) | Hoffmann-La Roche | 2024-12-30 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis (NCT07667322) | Hoffmann-La Roche | 2024-12-17 |
| An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment (NCT06675955) | Hoffmann-La Roche | 2024-12-13 |
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (NCT06588855) | Hoffmann-La Roche | 2024-12-11 |
| A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) (NCT06534983) | Hoffmann-La Roche | 2024-12-09 |
| A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (NCT06331598) | Hoffmann-La Roche | 2024-11-30 |
| A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT06624059) | Hoffmann-La Roche | 2024-11-18 |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms (NCT06774859) | Hoffmann-La Roche | 2024-10-27 |
| Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis (NCT05949580) | Hoffmann-La Roche | 2024-10-21 |
| A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) (NCT06780150) | Hoffmann-La Roche | 2024-09-26 |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06497556) | Hoffmann-La Roche | 2024-09-23 |
| A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (NCT06589986) | Hoffmann-La Roche | 2024-09-17 |
| A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors (NCT06537310) | Hoffmann-La Roche | 2024-09-16 |
| Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers (NCT06667414) | Hoffmann-La Roche | 2024-09-02 |
| A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy (NCT05861999) | Hoffmann-La Roche | 2024-08-14 |
| A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections (NCT06369220) | Hoffmann-La Roche | 2024-07-29 |
| A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization (NCT06503250) | Hoffmann-La Roche | 2024-07-19 |
| A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) (NCT05562947) | Hoffmann-La Roche | 2024-06-17 |
| A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy (NCT05861986) | Hoffmann-La Roche | 2024-05-30 |
| Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (NCT06439576) | Hoffmann-La Roche | 2024-05-09 |
| A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) (NCT06402838) | Hoffmann-La Roche | 2024-05-02 |
| A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy (NCT05808764) | Hoffmann-La Roche | 2024-04-26 |